COMMUNIQUÉS West-GlobeNewswire

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

21/02/2024 - 14:15

HANOVER, MD, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of [...]

Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

21/02/2024 - 14:01

Partnership Brings Pioneering Approach to Incorporating Advanced Colorectal Cancer Detection Into Country’s Healthcare System BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. ( [...]

Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024

21/02/2024 - 14:00

CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ( [...]

Route 92 Medical Announces Completion of Enrollment in the SUMMIT MAX Clinical Trial

21/02/2024 - 14:00

Randomized controlled trial designed to evaluate the safety and effectiveness of the Route 92 Medical 0.088” HiPoint Reperfusion Catheter, part of the Monopoint Reperfusion System SAN MATEO, Calif., Feb. 21, 2024 (GLOBE [...]

REPEAT: New report exposes harmful impact of Ford government’s privatization scheme on local public hospitals: Health Coalition

21/02/2024 - 14:00

Attn: Assignment Editor TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- As the Ford government counters horror stories about unprecedented emergency department wait times, burgeoning deficits, and an unrelenting staffing [...]

BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

21/02/2024 - 14:00

BURLINGTON, Mass. and JERUSALEM, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental [...]

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

21/02/2024 - 14:00

BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated [...]

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

21/02/2024 - 14:00

CONSHOHOCKEN, Pa., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today [...]

BioSyent Named to 2024 TSX Venture 50

21/02/2024 - 14:00

MISSISSAUGA, Ontario, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been named to the 2024 TSX Venture 50 list as one of the top [...]

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

21/02/2024 - 14:00

- Oral presentation to explore drug effect of sabirnetug (ACU193) on key cerebrospinal fluid biomarkers in early AD - Poster presentation to showcase method used to develop a first-of-its-kind assay to measure target [...]

Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology

21/02/2024 - 14:00

Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against challenging multi-pass [...]

Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

21/02/2024 - 14:00

WARREN, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]

CervoMed to Participate in the BIO CEO and Investor Conference

21/02/2024 - 14:00

BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company’s Management will [...]

Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach

21/02/2024 - 14:00

Virtual event on Friday, March 1, 2024 at 10:00 AM ET Event will feature GBS experts Lisa Butler of the GBS|CIDP Foundation International, Hugh Willison, MBBS, PhD, Professor Emeritus of Neurology of University of [...]

Halo Dental Technologies to Showcase New Digital Dental Mirror at CDS Chicago Midwinter Meeting

21/02/2024 - 14:00

New groundbreaking dental device marks a historic shift in daily-use dental instrument MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Halo Dental Technologies, a pioneering developer of innovative dental technologies, is [...]

aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants

21/02/2024 - 14:00

Individual Patient EAP allows access to efzofitimod for patients who complete the Phase 3 EFZO-FIT ™ study in pulmonary sarcoidosis. Company initiating program based on blinded EFZO-FIT ™ study investigator and patient [...]

Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19

21/02/2024 - 14:00

First Medicinal chemistry of an antiviral drug made of sugars BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT ), (the “Company”), a clinical stage biotechnology company developing [...]

Sharps Technology Enters Latin American Market and Receives First Orders for Securegard Disposable Smart Safety Syringes from Strategic Distribution Partner in Colombia

21/02/2024 - 14:00

Initial Orders for Sharps Securegard 1mL and 3mL Syringes are in Process, Introducing a Line of Competitively Priced, Low Waste, Smart Safety Syringes to the Colombian Healthcare System and the Latin American Market NEW [...]

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance

21/02/2024 - 13:30

Positive Adjusted EBITDA* for Q4 2023 more than doubles from Q3 2023 to $5 million (Net Loss of $2.8 million) leading to a significant turnaround for the full year versus 2022 Record quarterly revenue of $23.5 million [...]